Wei Z-H, He Q-B, Wang H, Su B-H, Chen H-Z
Department of Pharmacology and Biostatistics, College of Basic Medical Sciences, Jiaotong University, Shanghai, China.
J Neural Transm (Vienna). 2007;114(5):629-34. doi: 10.1007/s00702-007-0630-y. Epub 2007 Feb 23.
To determine the therapeutic effect of nootropic agent Cerebrolysin on patients with mild to moderate Alzheimer's disease (AD), we searched the Cochrane Library, Medline, PubMed, and Chinese Biomedical Literature Analysis and Retrieval System for Compact Disc (CBMDISC), and communicated with EBEWE Pharmaceutical Ltd, for randomized trials comparing Cerebrolysin with placebo in AD. Available data on clinical global impression, cognitive performance and activities of daily living were extracted from 6 randomized double-blind placebo-controlled clinical trials and combined with standard meta-analysis methods. An infusion with Cerebrolysin for 4 weeks (30 ml Cerebrolysin daily on five consecutive days of each week) led to a significant improvement of the clinical global impression. Compared with placebo, log(OR) was 1.1799, and 95% confident interval was 0.7463-1.6135 (P < 0.05), indicating that Cerebrolysin could significantly improve the clinical global impression in patients with mild to moderate AD. However, more convincing evidences are needed for the efficacy of Cerebrolysin on the cognitive performance and activities of daily living.
为确定促智药脑蛋白水解物对轻至中度阿尔茨海默病（AD）患者的治疗效果，我们检索了考克兰图书馆、医学在线数据库、医学期刊数据库以及中国生物医学文献光盘数据库，并与依比威制药有限公司联系，查找在AD患者中将脑蛋白水解物与安慰剂进行比较的随机试验。从6项随机双盲安慰剂对照临床试验中提取有关临床总体印象、认知表现和日常生活活动的现有数据，并采用标准的荟萃分析方法进行汇总。静脉输注脑蛋白水解物4周（每周连续5天，每天30ml脑蛋白水解物）可使临床总体印象显著改善。与安慰剂相比，对数比值比为1.1799，95%置信区间为0.7463 - 1.6135（P < 0.05），表明脑蛋白水解物可显著改善轻至中度AD患者的临床总体印象。然而，脑蛋白水解物对认知表现和日常生活活动疗效还需要更有说服力的证据。
Zotero 插件